Bayer’s Chinese Drug Filing and Analyst Upgrades Converge as Shares Extend 2025 Rally

Bayer shares gain 2.1% as investors welcome China Kerendia approval bid, Bergkamen site overhaul, and WHO partnership; earnings forecasts up 35%.

Bayer shares climbed for a second consecutive session on Thursday, adding 2.10 percent to close at €48.51, as investors digested a flurry of strategic developments ranging from a regulatory filing in China to a restructuring of the company’s largest active-ingredient production site. The stock has now surged 31.07 percent since the start of the year, placing it among the top performers in the DAX index.

The Leverkusen-based conglomerate submitted an application to China’s National Medical Products Administration seeking approval to expand the use of its kidney drug Kerendia (finerenone) to adults with chronic kidney disease not caused by diabetes. The filing, based on data from the Phase 3 FIND-CKD trial, targets a patient population that remains largely underserved: more than half of the estimated 850 million people worldwide living with chronic kidney disease have a non-diabetic etiology. According to Bayer, patients with advanced disease face a 2.6-times higher risk of kidney failure and cardiovascular events compared with the general population, even under standard therapy.

The FIND-CKD study, presented at the ERA Congress 2026 and published in the New England Journal of Medicine, marks the fifth completed Phase 3 trial to yield positive results for finerenone. Currently, the drug is approved in more than 100 countries only for patients with kidney disease linked to Type 2 diabetes and for certain forms of heart failure. An expanded indication in China would significantly broaden Kerendia’s addressable market and help Bayer diversify its nephrology portfolio away from its reliance on the shrinking Xarelto franchise.

Beyond the regulatory front, Bayer announced it will establish a wholly owned subsidiary for infrastructure and site services at its Bergkamen facility, its largest active-ingredient production hub with approximately 1,650 employees. The new entity, set to launch in 2027 under the leadership of Denis Panknin, aims to transform the site into a broader pharma and chemical park that already hosts external companies including Lanxess and Huntsman. Bayer invested roughly €50 million in the location in 2025.

Separately, the company extended its collaboration with the World Health Organization through 2030, donating 18 million tablets and ampoules valued at $15.5 million, plus an additional $9.45 million for program activities targeting Chagas disease, sleeping sickness, and tapeworm infections. While such commitments do not directly impact the bottom line, they bolster Bayer’s reputation at a time when the group has been dominated by litigation headlines.

Analyst sentiment has shifted markedly in Bayer’s favor. According to a Handelsblatt analysis, the stock ranks alongside BASF, Siemens Energy, and Infineon as one of the DAX components with the strongest upward revisions to earnings estimates: forecasts have risen 35 percent since April. The current price-to-earnings ratio stands at 10.4, a valuation discount that still reflects the roughly 67,000 pending glyphosate lawsuits. A potential settlement in that complex is anticipated by August 19.

Despite the year-to-date rally, Bayer shares remain 9.93 percent below their 52-week high of €53.86, reached on July 3. The combination of a promising regulatory pathway in China, infrastructure upgrades in Bergkamen, and growing analyst recognition paints a markedly more positive picture than the one facing the company a year ago. Yet the near-term trajectory will likely hinge on how the glyphosate litigation landscape evolves in the weeks ahead.